Company intelligence / Profile preview
Zurex Pharma
Middleton, Wisconsin, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Zurex Pharma has developed and commercialized a novel antimicrobial technology platform focused on infection prevention. Its lead product, ZuraGard, demonstrated less skin irritation and greater microbial reduction compared to standard CHG/isopropyl alcohol products in clinical trials. The company’s solutions target surgical site and catheter-related infections.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule (antiseptics/disinfectants)Device (applicator for antiseptics)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Zurex Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zurex Pharma.